BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 30995130)

  • 1. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy.
    Buchler T; Poprach A
    Target Oncol; 2024 Mar; 19(2):175-180. PubMed ID: 38308662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review.
    Massa G; Zambelli L; Zecca E; Shkodra M; Tinè G; Caraceni A
    Oncologist; 2024 Jun; 29(6):e728-e740. PubMed ID: 38518107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib.
    Volta AD; Delbarba A; Valcamonico F; Cappelli C; Caramella I; Bergamini M; Ferlin A; Berruti A
    In Vivo; 2023; 37(1):410-416. PubMed ID: 36593059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
    Bastin J; Werbrouck E; Verbiest A; Punie K; Bechter O; Woei-A-Jin FJ; Wolter P; Wildiers H; Lerut E; Dumez H; Decallonne B; Clement P; Vanderschueren D; Albersen M; Oyen R; Schöffski P; Beuselinck B
    Acta Clin Belg; 2019 Jun; 74(3):169-179. PubMed ID: 29774795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
    Miyazaki A; Miyake H; Harada K; Fujisawa M
    Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
    Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?
    Afshar M; Patel HRH; Jain A; Kumar A; Patel P; James ND; Porfiri E
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):529-532. PubMed ID: 30995130
    [No Abstract]   [Full Text] [Related]  

  • 10. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
    Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
    Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase inhibitors in renal cell carcinoma.
    Daste A; Grellety T; Gross-Goupil M; Ravaud A
    Expert Opin Pharmacother; 2014 Feb; 15(3):337-51. PubMed ID: 24328606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
    Diekstra MH; Swen JJ; Gelderblom H; Guchelaar HJ
    Expert Rev Mol Diagn; 2016; 16(5):605-18. PubMed ID: 26837796
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.